What is tirzepatide?
Tirzepatide is a peptide-based medicine that activates both glucose-dependent insulinotropic polypeptide (GIP) and glucagon-like peptide-1 (GLP-1) receptors. It has been evaluated in randomized clinical trials in metabolic disease and weight-management research.
It must not be confused with experimental injectable compounds marketed on supplier websites. Health Canada maintains product-specific approvals and publicly accessible Drug Identification Numbers for authorized tirzepatide medicines.
Clinical evidence and studied outcomes
Large randomized studies have assessed tirzepatide against placebo or comparators in defined patient populations. Important research endpoints include weight-related outcomes, metabolic indicators, treatment discontinuation and adverse-event incidence. Trial results should be read alongside inclusion criteria, follow-up duration and full safety reporting.
Evidence of a clinical effect does not establish that all similarly named products are equivalent. Formulation, manufacturing, regulated quality control and distribution channels matter.
Canadian product status
Health Canada’s Drug Product Database includes tirzepatide medicines such as Mounjaro and Zepbound, with individual DINs, product status and monographs. The current database should be checked for specific products rather than relying on a general statement that an ingredient is approved.
Authorized prescription products and unauthorized bulk or online injectable materials are not interchangeable. No supplier inclusion on this site should be interpreted as a recommendation to bypass lawful clinical and pharmacy pathways.
Safety and uncertainty
Clinicians consider gastrointestinal effects, product-specific warnings, other medical conditions and possible interactions when evaluating treatment. Clinical-trial participants are monitored under defined protocols; uncontrolled consumer use of unauthorized material lacks those safeguards.
Health Canada reported bacteria in some unauthorized injectable peptide products seized in November 2026. That warning illustrates how manufacturing and distribution risks can be separate from questions about the pharmacology of an active ingredient.
How to assess new claims
- Identify the exact authorized or investigational product rather than relying on the ingredient name.
- Look for randomized human trials with relevant comparators and meaningful outcomes.
- Check the official Canadian product status and monograph.
- Avoid interpreting supplier certificates as proof of clinical suitability.